Antibodies

7 May 2007

Affitech Signs Antibody Research and Licensing Agreement with Roche

5 May 2007

Abbott’s Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study

5 May 2007

Viragen Shifts Development Focus for Anti-Cancer Products

4 May 2007

Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor-co-positive metastatic breast cancer

4 May 2007

Data Presented at the American Academy on Neurology’s Annual Meeting Provide Update on Utilization and Safety of Tysabry(R) in Patients with Multiple Sclerosis

3 May 2007

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

3 May 2007

ThromboGenics Announces Progress With its Pre-Clinical and Clinical Programs

3 May 2007

Y’s Therapeutics Initiates Phase II Trial With YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury

2 May 2007

Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy

2 May 2007

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

1 May 2007

Dr. Reddy’s launches Reditux(TM) Monoclonal Antibody Treatment for Non-Hodgkin’s Lymphoma

1 May 2007

Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published

28 April 2007

Abbott’s HUMIRA(R) (adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn’s Disease

28 April 2007

CHMP Adopts Positive Opinion For Alexion’s Soliris(TM) In Europe

27 April 2007

PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study in Intravenous Steroid-Refractory Ulcerative Colitis

27 April 2007

Royalty Pharma and InNexus Biotechnology Announce Agreement Regarding the Purchase of Royalty Rights Based on DXL(TM) Antibody Products

25 April 2007

Y’s Therapeutics Completes Enrollment of Phase II Trial in the U.S. With YSPSL for Prevention of Delayed Graft Function in Renal Transplantation

24 April 2007

Micromet Achieves Milestone in BiTE(R) Research Collaboration with MedImmune

24 April 2007

KaloBios Licenses Humaneering(TM) Technology to Major Pharmaceutical Company

20 April 2007

MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE(R) Molecule

19 April 2007

Anti-Cancer Agent Avastin(R), Approved in Japan

19 April 2007

Viventia Biotech generates novel human anti-cancer antibody, VB1-050, and identifies its novel target

18 April 2007

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models

18 April 2007

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

18 April 2007

Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR

17 April 2007

YM BioSciences’ Partner Daiichi Sankyo Receives Clearance for Initial Clinical Trial in Japan

17 April 2007

Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

17 April 2007

Data Presented at AACR Meeting Shows Peregrine’s Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

13 April 2007

Genmab Initiates HuMax-EGFr Combination Study in Non Small Cell Lung Cancer

13 April 2007

XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ustekinumab (Stelara) Biosimilars Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Report Package: Bispecific Antibodies

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

PSMA-Targeted Therapy Pipeline Review